Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 4/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CSK | P41240 | 1/20 | 0.36 |
| ▸ | TPH1 | P17752 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924937 | 1.00 | GRB2 (0.43) | GRB2LCKLNPEPERAP2ERAP1 | |
| SCHEMBL21683275 | 0.81 | ANPEP (0.38) | HDAC1HDAC6SPHK1 | |
| Trifluoroacetic Acid SCHEMBL8479455 | 0.80 | PTPN1 (0.42) | — | |
| SCHEMBL21683255 | 0.80 | CTSS (0.45) | — | |
| SCHEMBL21683256 | 0.80 | CTSS (0.45) | — | |
| SCHEMBL18067861 | 0.73 | ALDH1A1 (0.49) | LNPEPERAP2ERAP1TPH1 | |
| SCHEMBL23924845 | 0.72 | EPHX2 (0.43) | GRB2LCK | |
| SCHEMBL23924843 | 0.72 | EPHX2 (0.43) | GRB2LCK | |
| SCHEMBL16976227 | 0.71 | KDM4E (0.54) | MAPT | |
| SCHEMBL23925183 | 0.71 | EPHX2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | GRB2 993/4885LCK 2416/4885LNPEP 1859/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | GRB2 993/4885LCK 2416/4885LNPEP 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.